Related Experiment Video
Updated: Jun 5, 2025

A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies
Published on: March 8, 2014
The significance of RB1 in multiple myeloma
Yiwen Wang1, Rui Yang1, Rui Liu1
1Department of Hematology, The Second Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, China.
Abstract:
The treatment of multiple myeloma (MM) has significantly advanced; however, the underlying genetic mechanisms remain elusive. Clonal events and genetic alterations are recognized as pivotal in the pathogenesis of MM. It is now understood that a multitude of gene mutations, including those affecting RAS, TP53, RB1, and 1q21 amplification, are prevalent in this disease. The incorporation of several high-risk genetic factors into the Second Revision of the International Staging System (R2-ISS) underscores the prognostic significance of genetic aberrations in MM. The retinoblastoma gene (RB1), located in 13q14, encodes the retinoblastoma protein (pRB), a tumor suppressor that regulates cell cycle progression. Deletion of RB1, which is a frequent event in MM, contributes to tumorigenesis by disrupting cell cycle control. In this respect, RB1 loss has been implicated in the progression of MM through its influence on interleukin-6 (IL-6) secretion and cell proliferation. This review comprehensively summarizes the role of RB1 in MM and expounds on the potential of targeting RB1 as a therapeutic strategy for this malignancy.
Insights
Retinoblastoma gene (RB1) loss is common in multiple myeloma (MM) and drives disease progression by affecting cell cycle control. Targeting RB1 presents a promising new therapeutic strategy for MM patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Multiple myeloma (MM) treatment has advanced, but its genetic underpinnings require further elucidation.
- Genetic alterations, including RAS mutations, TP53, RB1 deletions, and 1q21 amplification, are critical in MM pathogenesis.
- The R2-ISS system highlights the prognostic impact of genetic aberrations in MM.
Purpose of the Study:
- To review the role of the retinoblastoma gene (RB1) in multiple myeloma.
- To explore the therapeutic potential of targeting RB1 in MM.
Main Methods:
- Literature review summarizing genetic alterations in MM.
- Analysis of RB1's function as a tumor suppressor and its role in cell cycle regulation.
- Examination of RB1's impact on MM progression and IL-6 secretion.
Main Results:
- RB1 deletion is a frequent event in MM, contributing to uncontrolled cell proliferation.
- RB1 loss influences interleukin-6 secretion and overall MM progression.
- The retinoblastoma protein (pRB) is crucial for regulating cell cycle progression.
Conclusions:
- RB1 plays a significant role in the development and progression of multiple myeloma.
- Targeting RB1 offers a potential therapeutic avenue for managing MM.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Negative Regulator Molecules
The Ras Gene
Ras is a...
Non-LTR Retrotransposons
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

